Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
1986-7-23
|
pubmed:abstractText |
Polyethylene glycol (PEG)-L-asparaginase, at doses ranging from 500 to 8000 units/m2, was infused iv over 60 min in 31 patients of whom 27 were evaluable pharmacokinetically. The plasma disappearance of PEG-L-asparaginase is described by a monophasic curve with a mean half-life of 357 +/- 243 hr which is much longer than that of the unconjugated enzyme (half-life of approximately 20 hr). The rate of total clearance (128 +/- 74 ml/m2 X day) is much slower than that of L-asparaginase (2196 +/- 1098 ml/m2 X day). The volume of distribution is 2093 +/- 643 ml/m2, which is similar to that of L-asparaginase, indicating that PEG-L-asparaginase is mainly localized in the plasma. No enzyme could be measured in urine samples taken from nine patients for a period of up to 4 days. Additionally, no enzyme was measurable in one patient's pleural fluid obtained at the end of infusion and 6 days after infusion of a 1000-unit/m2 dose; the corresponding concentrations in plasma were 0.64 and 0.62 units/ml, respectively. In general, the plasma enzyme concentrations at the end of the 1-hr infusion and at 14 days after drug administration were proportional to the dose given. However, in two patients, a sudden disappearance of enzyme levels occurred which preceded anaphylactic reactions during subsequent treatment. A third patient developed severe bronchospasm 30 min after the first dose, but his enzyme levels were within the normal range.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0090-9556
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
14
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
349-52
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:2872037-Adult,
pubmed-meshheading:2872037-Aged,
pubmed-meshheading:2872037-Anaphylaxis,
pubmed-meshheading:2872037-Asparaginase,
pubmed-meshheading:2872037-Dose-Response Relationship, Drug,
pubmed-meshheading:2872037-Drug Evaluation,
pubmed-meshheading:2872037-Female,
pubmed-meshheading:2872037-Humans,
pubmed-meshheading:2872037-Infusions, Parenteral,
pubmed-meshheading:2872037-Kinetics,
pubmed-meshheading:2872037-Leukemia, Lymphoid,
pubmed-meshheading:2872037-Leukemia, Myeloid,
pubmed-meshheading:2872037-Leukemia, Myeloid, Acute,
pubmed-meshheading:2872037-Lymphoma,
pubmed-meshheading:2872037-Male,
pubmed-meshheading:2872037-Middle Aged,
pubmed-meshheading:2872037-Polyethylene Glycols
|
pubmed:articleTitle |
Clinical pharmacology of polyethylene glycol-L-asparaginase.
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|